-
Aiming to solve the problem of side effects of IL-2 immunotherapy, Xinrui completes US$55 million in Series A financing
Time of Update: 2021-03-27
The company's main product candidate, AB248, is a fusion protein that selectively activates the IL-2 receptor signaling pathway in CD8-positive T cells.
-
FDA News | Pembrolizumab combination program approved as first-line treatment for advanced esophageal cancer or GEJ cancer
Time of Update: 2021-03-27
0001), and the risk of death was reduced by 27%; the 12-month OS was 51%, compared with the chemotherapy group (39%) Increased by 12%; median PFS was 6.
-
The research team of He Housheng/Wei Gonghong/Ren Shancheng collaborated to discover a new mechanism for regulating prostate cancer
Time of Update: 2021-03-27
On March 19, Professor Ren Shancheng from Shanghai Changhai Hospital, Professor Wei Gonghong from Fudan University School of Basic Medicine and Affiliated Tumor Hospital (formerly at the University of Oulu, Finland), and Professor He Housheng from the University of Toronto in Canada teamed up in Nature Communications An article published in the journal CRISPRi screens reveals a DNA methylation-mediated 3D genome dependent causal mechanism in prostate cancer.
-
JAMA Sub-Journal: These advanced breast cancers are expected to be cured! Chinese scholars propose to modify the stage of the disease
Time of Update: 2021-03-27
Recently, JAMA Network Open, a sub-issue of the Journal of the American Medical Association, published a case analysis study that showed that stage IV breast cancer with distant lymph node metastasis can be regarded as a local disease and is expected to be cured through active treatment.
-
Literature Sharing | "Uncertain" UroVysion Fluorescence In Situ Hybridization Results: Clinical Significance of Diagnostic Terms
Time of Update: 2021-03-27
The UroVysion FISH results of some cases in clinical testing have 1-3 abnormal cells.
The purpose of this study is to clarify the incidence and clinical significance of these uncertain UroVysion results.
Overall, the incidence of secondary malignancies in the UroVysion group with uncertain results (14/59, 23.
-
Interpretation of the global consensus on screening and eradicating Hp and preventing gastric cancer is here! Important recommendation see here
Time of Update: 2021-03-27
This point is consistent with the "Expert Consensus Opinions on Helicobacter Pylori Eradication and Gastric Cancer Prevention and Control in China" published in my country in 2019 [3].
Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus.
-
Precision therapy for advanced gynecological cancer yields positive results, BeiGene has China development rights
Time of Update: 2021-03-27
▎The content team editor of WuXi AppTec today, Leap Therapeutics announced its new target DKK1 inhibitor DKN-01 as a single drug or in combination with paclitaxel, in the treatment of advanced gynecological cancer phase 2 "basket" clinical trial (Basket trial) to obtain positive results.
-
Summit Dialogues to Participate in the Grand Event | Focus on the first cwCLL and iwCLL joint conference
Time of Update: 2021-03-27
On March 20, 2021, the 4th China Chronic Lymphocytic Leukemia Conference and the 1st China Chronic Lymphocytic Leukemia Working Group (cwCLL) and International Chronic Lymphocytic Leukemia Working Gr
-
Harvard's HPV vaccination should be given as early as possible, and the cancer prevention effect will be reduced for those over 26!
Time of Update: 2021-03-27
People over 26 years of age are vaccinated with HPV vaccine effectiveness and cancer prevention potential is low.
-
Thinking from a clinical perspective: mechanism research + focus on the crowd + large samples, perfect!
Time of Update: 2021-03-27
Figure 2 Cox regression analysis of IFNα, IFNγ, TNFα and TGFβ pathways and different subtypes of breast cancer recurrence risk.
-
Nature: Bacterial peptides on the surface of tumor cells are expected to become a new target for cancer immunotherapy
Time of Update: 2021-03-27
com" target="_blank">/---Cancer immunotherapy may be promoted in an unexpected direction: bacteria residing in tumor cells.
com/course/tags/%E7%BB%86%E8%83%9E%E7%94%9F%E7%89%A9%E5%AD%A6/">Cell Biology at the Weizmann Institute of Science has studied molecular "markers"-protein fragments on the cell surface, or peptides, which can mark cancer cells as foreign and may therefore become immunotherapy.
-
Fancy contenders for antibody drugs
Time of Update: 2021-03-27
▲The second TG-Bio immune technology conference in Bioogo 2021 ▲Currently, there are more than one hundred antibody drugs approved for marketing worldwide, involving 58 targets.
In addition, these small molecule inhibitors may not directly compete with antibody drugs with the same target.
-
Higher activity than existing targeted drugs, new expectations for ovarian cancer, fallopian tube cancer and peritoneal cancer
Time of Update: 2021-03-27
For a long time in global clinical trials, we have been studying targeted drugs for tumor driver genes, such as directly anchoring EGFR or ALK gene mutations, and inhibiting tumors through the combination of drugs with proteins translated by the mutant genes.
-
Freshly released | 2021 SGO LBA blockbuster research solves the mystery!
Time of Update: 2021-03-27
The study aims to explore the efficacy and safety of olaparib, olaparib+cediranib versus cediranib as a single agent for endometrial cancer patients.
The Phase Ib KEYNOTE-028 study showed that pembrolizumab showed certain anti-tumor activity in PD-L1-positive vulvar cancer patients with an ORR of 6%.
-
PROTAC new technology opens a new field of tumor targeted therapy
Time of Update: 2021-03-27
▶ After the establishment of Arvinas, companies such as C4 Therapeutics and Kymera Therapeutics were established one after another, dedicated to exploring the therapeutic potential of small molecule protein degradation agents, and constantly making new contributions in the field of PROTAC technology.
▶ ARV-110, an oral protein degrading agent targeting AR, is the world's first PROTAC drug to enter clinical trials.
-
Huazhong University of Science and Technology and other organizations cooperated with Chen Gang/Zhang Qinghua and others to develop new classification methods to better treat cervical cancer
Time of Update: 2021-03-27
On March 18, 2021, Chen Gang, Zhang Qinghua and Hu Zheng of Huazhong University of Science and Technology jointly published an online publication titled "A Fifteen-Gene Classifier to Predict Neoadjuvant Chemotherapy Responses in Patients with Stage IB to IIB Squamous Cervical" in Advanced Science (IF=16) Cancer" research paper, the study identified patient-specific somatic mutations that caused NACT non-response through whole exome sequencing.
-
Shanghai Jiaotong University Duan Yourong/Lin Houwen/Liao Hongze The development of new protein inhibitors has important reference significance for the control of tumor blood-borne metastasis
Time of Update: 2021-03-27
This study generally demonstrates the feasibility of using DR6/APP interaction to regulate transendothelial migration of blood-borne tumor cells, and provides PEG-tAHP-DRI as a DR6/APP interaction for the development of anti-blood-borne metastasis therapies A novel and promising inhibitor.
-
New Drug Development: Anti-HER3 Targeted Therapy 30 Years of Creeping Road
Time of Update: 2021-03-27
The pan-HER family inhibitor Sym013 is a mixture of six humanized full-length monoclonal antibodies against three targets of EGFR, HER2, and HER3, and has been shown to reduce the growth of cancer cells in vivo and in vitro.
-
Nat Commun: The important role and therapeutic potential of PRAK in tumor metastasis
Time of Update: 2021-03-26
Knockout of the Prak gene will inhibit the distant metastasis of the tumor but will not affect the growth of the primary tumorIt is worth noting that the pharmacological inactivation of PRAK with clinically relevant inhibitors can reproduce the anti-metastatic effect of knocking out Prak, thus highlighting the therapeutic potential of targeting PRAK in the control of tumor metastasis.
-
Br J Cancer: A few cups of coffee or tea a day can improve the survival rate of breast cancer patients
Time of Update: 2021-03-26
The results showed that increased coffee intake after diagnosis was associated with a decrease in breast cancer-specific mortality: compared to non-drinkers, drinking more than 3 cups of coffee a day corresponds to a 25% reduction in the risk of death.
